Aristotle University Of Thessaloniki (AUTH)
Σημασία της τριμεταζιδίνης στη μείωση της μυοκαρδιακής νέκρωσης και στην πρόγνωση μετά από επεμβάσεις αορτοστεφανιαίας παράκαμψης και αγγειοπλαστικής
Abstract
dc:descriptionThe aim of this study is to evaluate whether the administration of piperazine derivative trimetazidine (TMZ) in patients before and after revascularization procedures -PCI and CABG- minimizes the PCI/CABG induced myocardial damage. Trimetazidine exerts its anti-ischaemic effect on the heart using a metabolic pathway. TMZ reduces fatty acid oxidation, stimulates glucose oxidation and induces further ATP production. This is accomplished by a selective inhibition of long chain 3-KAT enzyme of free fatty acid β-oxidation. In conditions of ischaemia, the preferential breakdown of glycogen improves energy metabolism, because ATP resynthesis requires less oxygen. TMZ exerts its antiischaemic properties without reducing oxygen consumption or increasing oxygen supply, since no significant changes in heart rate, blood pressure or rate-pressure product have been observed. Hundred patients who underwent revascularization procedure were included in this study. More specifically, 51 patients who underwent PCI formed two groups, Group A-trimetazidine group (n=27) and Group B-traditional therapy group (n=24) and 49 patients who underwent CABG formed groups C-trimetazidine group (n=23) and D-traditional therapy (n=26), respectively. All patients received conventional antianginal therapy and patients of Groups A and C received, in addition, 20mgr trimetazidine orally every 8h, started 15 days before revascularization and continued for three months after the procedure. A detailed medical history was taken from each patient (sex, age, BMI, risk factors of coronary artery disease, previous medical history) and angiographic findings were registered as well as the exact coronary artery location where PCI or CABG was performed. A complete biochemical examination was performed for each patient 24h after revascularization, except from patient’s lipidaemic profile, which was defined before revascularization procedure. Serum troponine I and CK-MB levels were measured before revascularization, 6h, 24h and 48h afterwards, in order to determine the size of myocardial damage caused. 2D cardiac ECHO was performed in each patient before revascularization and it was repeated one and three months afterwards. All ECHO measurements were performed in the same ECHO laboratory. Left ventricular (LV) dimensions and ejection farction (EF) were measured each time. Global and regional left ventricular wall motion were estimated while hypokinetic, akinetic or dyskinetic regions were noted. EF was considered as good when it was measured ≥50%, moderate when EF=35-50% and poor when EF≤35%. Antianginal therapy administered after PCI was recorded for each patient of two groups. Conventional antianginal treatment includes b-blockers, ACE-inhibitors, statins, nitrates, aspirin, and clopidogrel. The revascularization procedure outcome was checked in one and three months` time for each patients and rehospitalization was recorded. Fifty one patients, 40 men and 11 women, formed the two groups of patients who underwent PCI. Group A patients aged 63.2, while patients of group B, 61.7 years old. The frequency of occurrence of CAD risk factors among these patients was: hypertension 66% in group A-60% in group B, diabetes mellitus 15% and 12% respectively, smoking 52% and 56%, hypercholesterolaemia 52% and 60%, family CAD history 30% and 32%, luck of exercise 77% and 76%, BMI 26,6 in group A and 27,2 in group B. There were no statistically significant differences in terms of sex, age BMI, risk factors and previous medical history as well as medical treatment before and after PCI between two groups. Statistical analysis of troponine I and CK-MB levels measurements showed that trimetazidine administration minimizes myocardial damage caused during PCI procedure, but does not influence other biochemical parameters measured. Referring to global and regional wall motion of LV, there is a statistically significant improvement of both EF and hypokinetic, dyskinetic or akinetic regions of LV in patients of group A, who received additionally trimetazidine. More specifically, 11 patients of group A had EF<50% before PCI, but only three of them still had EF<50% after one months` time and just one in three months` time. On the other hand, 8 patients of group B had EF<50% before PCI, four patients after one and three months` time. Statistically significant improvement of both posterior and inferior wall motion was detected in patients of group A. No statistically significant difference was found between two groups, referring to rehospitalization for acute coronary events. Restenosis occurred in one patient of group B three months after PCI. The same procedure was followed in order to process data of 49 patients who underwent CABG – 36 men and 13 women. Patients of group C aged 65.7 years old and patients of group D 65.1 years old, respectively. The frequency of occurrence of CAD risk factors was: hypertension 78% in group C-77% in group D, diabetes mellitus 48% and 38% respectively, smoking 52% and 65%, hypercholesterolaemia 57% and 65%, family CAD history 26% and 31%, luck of exercise 87% and 85%, BMI 27.3 in group C and 27.6 in group D. There were no statistically significant differences in terms of sex, age BMI, risk factors and previous medical history as well as medical treatment before and after CABG between two groups. Positive effects of trimetazidine administration in size of myocardial damage resulted after statistical analysis of troponine I and CK-MB measurements of patients underwent CABG. As a result, trimetazidine appears to minimizes CABG induced myocardial necrosis, but do not affect other biochemical parameters. Global and regional wall motion was improved too, after trimetazidine administration. More specifically, 10 patients of group C had EF<50% before CABG, five patients had EF<50% after one months` time and four in three months` time. Referring to group D, 8 patients had EF<50% before PCI, whose EF measurement remained <50% after one month and four patients had EF<50% in three months` time. Statistically significant improvement of regional wall motion was recorded, especially referring to inferior wall motion, in patients of group C. No statistically significant difference was found between two groups, referring to rehospitalization for acute coronary events.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Lambrou, Alexandra
- Λάμπρου, Αλεξάνδρα
Subjects
dc:subject × 20- Τριμεταζιδίνη
- Αορτοστεφανιαία παράκαμψη
- Αγγειοπλαστική
- Μεταβολικός παράγοντας
- Μυοκαρδιακή νέκρωση
- Τροπονίνη Ι
- Κρεατινίκη κινάση ΜΒ
- Κλάσμα εξώθησης
- Trimetazidine
- Coronary artery bypass grafting
- Percutaneous coronary intervention
- Metabolic agent
- Myocardial damage
- Troponine I
- Creatine kinase MB
- Ejection fraction
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19569